scholarly journals Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits againstVibrio choleraeO1 challenge

2009 ◽  
Vol 56 (2) ◽  
pp. 179-184 ◽  
Author(s):  
Juthika Kundu ◽  
Rupa Mazumder ◽  
Ranjana Srivastava ◽  
Brahm S. Srivastava
2004 ◽  
Vol 72 (2) ◽  
pp. 1184-1187 ◽  
Author(s):  
Charlotte Larsson ◽  
Jan Holmgren ◽  
Gunnar Lindahl ◽  
Charlotta Bergquist

ABSTRACT Intranasal immunization of mice with Rib, a cell surface protein of group B streptococcus (GBS), conjugated to or simply coadministered with the recombinant cholera toxin B subunit, induces systemic immunoglobulin G (IgG) and local IgA antibody responses and confers protection against lethal GBS infection. These findings have implications for the development of a human GBS vaccine.


2006 ◽  
Vol 74 (8) ◽  
pp. 4939-4944 ◽  
Author(s):  
F. C. Pimenta ◽  
E. N. Miyaji ◽  
A. P. M. Arêas ◽  
M. L. S. Oliveira ◽  
A. L. S. S. de Andrade ◽  
...  

ABSTRACT One of the candidate proteins for a mucosal vaccine antigen against Streptococcus pneumoniae is PsaA (pneumococcal surface antigen A). Vaccines targeting mucosal immunity may raise concerns as to possible alterations in the normal microbiota, especially in the case of PsaA, which was shown to have homologs with elevated sequence identity in other viridans group streptococci. In this work, we demonstrate that intranasal immunization with a cholera toxin B subunit-PsaA fusion protein is able to protect mice against colonization with S. pneumoniae but does not significantly alter the natural oral or nasopharyngeal microbiota of mice.


2001 ◽  
Vol 69 (1) ◽  
pp. 297-306 ◽  
Author(s):  
Xuzhuang Shen ◽  
Teresa Lagergård ◽  
Yonghong Yang ◽  
Marianne Lindblad ◽  
Margareta Fredriksson ◽  
...  

ABSTRACT Group B Streptococcus (GBS) type III capsular polysaccharide (CPS III) was conjugated to recombinant cholera toxin B subunit (rCTB) using three different methods which employed (i) cystamine and N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), (ii) carbodiimide with adipic acid dihydrazide (ADH) as a spacer, or (iii) reductive amination (RA). The CPS III-rCTB conjugates were divided into large- and small-molecular-weight (M r) fractions, and the immunogenicities of the different preparations after intranasal (i.n.) immunization were studied in mice. Both large- and small-M rconjugates of CPS III-rCTBRA or CPS III-rCTBADHinduced high, almost comparable levels of CPS-specific immunoglobulin G (IgG) in serum, lungs, and vagina that were generally superior to those obtained with CPS III-rCTBSPDP conjugates or a CPS III and rCTB mixture. However, the smaller-M rconjugates of CPS III-rCTBRA or CPS III-rCTBADHin most cases elicited a lower anti-CPS IgA immune response than the large-M r conjugates, and the highest anti-CPS IgA titers in both tissues and serum were obtained with the large-M r CPS III-rCTBRA conjugate. Serum IgG anti-CPS titers induced by the CPS III-rCTBRAconjugate had high levels of specific IgG1, IgG2a, IgG2b, and IgG3 antibodies. Based on the effectiveness of RA for coupling CPS III to rCTB, RA was also tested for conjugating GBS CPS Ia with rCTB. As for the CPS III-rCTB conjugates, the immunogenicity of CPS Ia was greatly increased by conjugation to rCTB. Intranasal immunization with a combination of CPS Ia-rCTB and CPS III-rCTB conjugates was shown to induce anti-CPS Ia and III immune responses in serum and lungs that were fully comparable with the responses to immunization with the monovalent CPS Ia-rCTB or CPS III-rCTB conjugates. These results suggest that the GBS CPS III-rCTB and CPS Ia-rCTB conjugates prepared by the RA method may be used in bivalent and possibly also in multivalent mucosal GBS conjugate vaccines.


Vaccine ◽  
1997 ◽  
Vol 15 (10) ◽  
pp. 1110-1113 ◽  
Author(s):  
Bernard de Geus ◽  
Maike Dol-Bosman ◽  
Jan Willem Scholten ◽  
Wil Stok ◽  
Andre Bianchi

Pharmaceutics ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 576
Author(s):  
Micaela A. Reeves ◽  
Joshua M. Royal ◽  
David A. Morris ◽  
Jessica M. Jurkiewicz ◽  
Nobuyuki Matoba ◽  
...  

Epicertin (EPT) is a recombinant variant of the cholera toxin B subunit, modified with a C-terminal KDEL endoplasmic reticulum retention motif. EPT has therapeutic potential for ulcerative colitis treatment. Previously, orally administered EPT demonstrated colon epithelial repair activity in dextran sodium sulfate (DSS)-induced acute and chronic colitis in mice. However, the oral dosing requires cumbersome pretreatment with sodium bicarbonate to conserve the acid-labile drug substance while transit through the stomach, hampering its facile application in chronic disease treatment. Here, we developed a solid oral formulation of EPT that circumvents degradation in gastric acid. EPT was spray-dried and packed into enteric-coated capsules to allow for pH-dependent release in the colon. A GM1-capture KDEL-detection ELISA and size-exclusion HPLC indicated that EPT powder maintains activity and structural stability for up to 9 months. Capsule disintegration tests showed that EPT remained encapsulated at pH 1 but was released over 180 min at pH 6.8, the approximate pH of the proximal colon. An acute DSS colitis study confirmed the therapeutic efficacy of encapsulated EPT in C57BL/6 mice upon oral administration without gastric acid neutralization pretreatment compared to vehicle-treated mice (p < 0.05). These results provide a foundation for an enteric-coated oral formulation of spray-dried EPT.


Sign in / Sign up

Export Citation Format

Share Document